Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $11.9 million.

  • Fulcrum Therapeutics' Gains from Investment Securities rose 187846.42% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 69138.57%. This contributed to the annual value of $9.4 million for FY2024, which is 619.24% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Gains from Investment Securities stood at $11.9 million, which was up 187846.42% from $12.1 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Gains from Investment Securities high stood at $12.1 million for Q2 2025, and its period low was $100000.0 during Q1 2021.
  • In the last 5 years, Fulcrum Therapeutics' Gains from Investment Securities had a median value of $700000.0 in 2024 and averaged $4.1 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 9901.13% in 2024, then soared by 1198231.2% in 2025.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Gains from Investment Securities stood at $500000.0 in 2021, then crashed by 80.0% to $100000.0 in 2022, then surged by 10008.77% to $10.1 million in 2023, then tumbled by 94.06% to $600000.0 in 2024, then surged by 1878.46% to $11.9 million in 2025.
  • Its Gains from Investment Securities stands at $11.9 million for Q3 2025, versus $12.1 million for Q2 2025 and $12.0 million for Q1 2025.